PURPOSE: Alcohol intake is associated with increased risk of breast cancer. In contrast, the relation between alcohol consumption and breast cancer survival is less clear. PATIENTS AND METHODS: We assessed pre- and postdiagnostic alcohol intake in a cohort of 22,890 women with incident invasive breast cancer who were residents of Wisconsin, Massachusetts, or New Hampshire and diagnosed from 198 to 200 at ages 20 to 79 years. All women reported on prediagnostic intake; a subsample of 4,881 reported on postdiagnostic intake. RESULTS: During a median follow-up of 11.3 years from diagnosis, 7,780 deaths occurred, including 3,484 resulting from breast cancer. Hazard ratios (HR) and 95% CIs were estimated. Based on a quadratic analysis, moderate alcohol consumption before diagnosis was modestly associated with disease-specific survival (compared with nondrinkers, HR = 0.93 [95% CI, 0.85 to 1.02], 0.85 [95% CI, 0.75 to 0.95], 0.88 [95% CI, 0.75 to 1.02], and 0.89 [95% CI, 0.77 to 1.04] for two or more, three to six, seven to nine, and ≥ 10 drinks/wk, respectively). Alcohol consumption after diagnosis was not associated with disease-specific survival (compared with nondrinkers, HR = 0.88 [95% CI, 0.61 to 1.27], 0.80 [95% CI, 0.49 to 1.32], 1.01 [95% CI, 0.55 to 1.87], and 0.83 [95% CI, 0.45 to 1.54] for two or more, three to six, seven to nine, and ≥ 10 drinks/wk, respectively). Results did not vary by beverage type. Women consuming moderate levels of alcohol, either before or after diagnosis, experienced better cardiovascular and overall survival than nondrinkers. CONCLUSION: Overall alcohol consumption before diagnosis was not associated with disease-specific survival, but we found a suggestion favoring moderate consumption. There was no evidence for an association with postdiagnosis alcohol intake and breast cancer survival. This study, however, does provide support for a benefit of limited alcohol intake for cardiovascular and overall survival in women with breast cancer.
PURPOSE:Alcohol intake is associated with increased risk of breast cancer. In contrast, the relation between alcohol consumption and breast cancer survival is less clear. PATIENTS AND METHODS: We assessed pre- and postdiagnostic alcohol intake in a cohort of 22,890 women with incident invasive breast cancer who were residents of Wisconsin, Massachusetts, or New Hampshire and diagnosed from 198 to 200 at ages 20 to 79 years. All women reported on prediagnostic intake; a subsample of 4,881 reported on postdiagnostic intake. RESULTS: During a median follow-up of 11.3 years from diagnosis, 7,780 deaths occurred, including 3,484 resulting from breast cancer. Hazard ratios (HR) and 95% CIs were estimated. Based on a quadratic analysis, moderate alcohol consumption before diagnosis was modestly associated with disease-specific survival (compared with nondrinkers, HR = 0.93 [95% CI, 0.85 to 1.02], 0.85 [95% CI, 0.75 to 0.95], 0.88 [95% CI, 0.75 to 1.02], and 0.89 [95% CI, 0.77 to 1.04] for two or more, three to six, seven to nine, and ≥ 10 drinks/wk, respectively). Alcohol consumption after diagnosis was not associated with disease-specific survival (compared with nondrinkers, HR = 0.88 [95% CI, 0.61 to 1.27], 0.80 [95% CI, 0.49 to 1.32], 1.01 [95% CI, 0.55 to 1.87], and 0.83 [95% CI, 0.45 to 1.54] for two or more, three to six, seven to nine, and ≥ 10 drinks/wk, respectively). Results did not vary by beverage type. Women consuming moderate levels of alcohol, either before or after diagnosis, experienced better cardiovascular and overall survival than nondrinkers. CONCLUSION: Overall alcohol consumption before diagnosis was not associated with disease-specific survival, but we found a suggestion favoring moderate consumption. There was no evidence for an association with postdiagnosis alcohol intake and breast cancer survival. This study, however, does provide support for a benefit of limited alcohol intake for cardiovascular and overall survival in women with breast cancer.
Authors: Shumin M Zhang; I-Min Lee; JoAnn E Manson; Nancy R Cook; Walter C Willett; Julie E Buring Journal: Am J Epidemiol Date: 2007-01-04 Impact factor: 4.897
Authors: Jane Key; Susan Hodgson; Rumana Z Omar; Tina K Jensen; Simon G Thompson; Alan R Boobis; Donald S Davies; Paul Elliott Journal: Cancer Causes Control Date: 2006-08 Impact factor: 2.506
Authors: Kerryn W Reding; Janet R Daling; David R Doody; Cecilia A O'Brien; Peggy L Porter; Kathleen E Malone Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07-29 Impact factor: 4.254
Authors: M E Reichman; J T Judd; C Longcope; A Schatzkin; B A Clevidence; P P Nair; W S Campbell; P R Taylor Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: M P Longnecker; P A Newcomb; R Mittendorf; E R Greenberg; R W Clapp; G F Bogdan; J Baron; B MacMahon; W C Willett Journal: J Natl Cancer Inst Date: 1995-06-21 Impact factor: 13.506
Authors: Vicki Hart McLaughlin; Amy Trentham-Dietz; John M Hampton; Polly A Newcomb; Brian L Sprague Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-01-08 Impact factor: 4.254
Authors: Paul Lochhead; Reiko Nishihara; Zhi Rong Qian; Kosuke Mima; Yin Cao; Yasutaka Sukawa; Sun A Kim; Kentaro Inamura; Xuehong Zhang; Kana Wu; Edward Giovannucci; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino Journal: Am J Clin Nutr Date: 2015-09-30 Impact factor: 7.045
Authors: Christopher Thomas Veal; Vicki Hart; Susan G Lakoski; John M Hampton; Ronald E Gangnon; Polly A Newcomb; Stephen T Higgins; Amy Trentham-Dietz; Brian L Sprague Journal: J Cancer Surviv Date: 2017-01-05 Impact factor: 4.442
Authors: Sarah J Lowry; Kris Kapphahn; Rowan Chlebowski; Christopher I Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-19 Impact factor: 4.254
Authors: Michael N Passarelli; Polly A Newcomb; John M Hampton; Amy Trentham-Dietz; Linda J Titus; Kathleen M Egan; John A Baron; Walter C Willett Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544